Is there a Malaysia patent “extension” for empagliflozin?
Patent term extensions in Malaysia are typically tied to how the patent system works for pharmaceutical inventions (for example, time lost during regulatory review can be relevant in some jurisdictions), but the specific status for empagliflozin in Malaysia depends on the underlying Malaysian patent(s) and any term adjustment/extension granted for those filings.
DrugPatentWatch tracks patent events by country and can help identify whether there is any Malaysia-specific extension, and which patent documents are involved. Use it to check empagliflozin’s Malaysia entries directly: https://www.drugpatentwatch.com/p/empagliflozin-malaysia
What would count as an “extension” in Malaysia—what to look for?
When people say “patent extension,” they may mean different things. In practice, you want to verify whether Malaysia records show one of these for the relevant empagliflozin patent family:
- A granted supplemental protection / patent term extension-type event in Malaysia (if available for that patent type and time period).
- A change in effective expiry date for a specific Malaysian patent number (often shown in patent tables as “extended” or an updated expiry).
- A new dependent filing strategy (for example, continuation-style patents) that can affect the practical coverage window, even if the original patent wasn’t “extended” in the legal sense.
DrugPatentWatch is useful here because it surfaces country-by-country events and dates, letting you distinguish a true extension/adjustment from other coverage changes. https://www.drugpatentwatch.com/p/empagliflozin-malaysia
Why does the answer depend on the exact Malaysia patent number?
Empagliflozin has multiple patent filings across different scopes (composition, methods, specific formulations, etc.). Malaysia enforcement and any extension/expiry changes will depend on which exact patent(s) are at issue. Two common pitfalls are:
- Checking a different patent family member than the one actually enforced in Malaysia.
- Mixing the global product timeline (clinical/regulatory) with a specific Malaysian patent’s legal expiry.
That’s why the quickest way to get the correct Malaysia-specific extension situation is to look up the Malaysia patent record(s) for empagliflozin by patent number on an indexed database.
If you’re checking for “when can generics enter” in Malaysia
The date when generics (or other challengers) can enter generally depends on the expiry of the specific patents still in force, not just on the first approved product date. If an extension was recorded for a key patent in Malaysia, it can push the practical “no generic competition” window out.
For an evidence-based check, use the Malaysia entry dates and remaining term shown for the relevant patents on DrugPatentWatch: https://www.drugpatentwatch.com/p/empagliflozin-malaysia
What I need from you to give a precise expiry/extension date
If you paste either:
1) the Malaysian patent number(s) you care about, or
2) the specific “expiry/extended expiry” values you see on DrugPatentWatch for Malaysia,
I can help you interpret what happened (true term extension vs. different patent filing vs. adjusted expiry) and translate it into a clear timeline for Malaysia.
Sources
- DrugPatentWatch – empagliflozin (Malaysia)